Atossa Therapeutics
ATOS
12 hedge funds and large institutions have $175K invested in Atossa Therapeutics in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
9% more funds holding
Funds holding: 11 → 12 (+1)
0.03% less ownership
Funds ownership: 0.04% → 0.01% (-0.03%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
63% less capital invested
Capital invested by funds: $478K → $175K (-$303K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.8K |
| 2 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
+$22.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.55K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$1.02K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$509 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$131K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$27K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.11K |
| 4 |
MFW
Mosaic Family Wealth
St. Louis,
Missouri
|
-$1K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$509 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $78K | +$30.8K | +423 | +34% |
|
|
PAM
2
Panagora Asset Management
Boston,
Massachusetts
| $52K | -$2.11K | -29 | -3% |
|
|
KWM
3
Kingsview Wealth Management
Grants Pass,
Oregon
| $15K | +$22.6K | +311 | New |
|
|
VF
4
Virtu Financial
New York
| $12K | -$73 | -1 | -0.4% |
|
|
GLA
5
Good Life Advisors
Reading,
Pennsylvania
| $6K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $6K | +$2.55K | +35 | +39% |
|
|
7
Renaissance Technologies
New York
| $3K | -$131K | -1,804 | -97% |
|
8
BlackRock
New York
| $2K | – | – | – |
|
|
9
Parallax Volatility Advisers
San Francisco,
California
| $1K | +$1.02K | +14 | New |
|
|
TSS
10
Two Sigma Securities
New York
| – | -$27K | -279 | Closed |
|
|
MFW
11
Mosaic Family Wealth
St. Louis,
Missouri
| – | -$1K | -7 | Closed |
|
|
12
Wells Fargo
San Francisco,
California
| – | -$509 | -7 | -54% |
|
|
TL
13
TrueWealth LLC
Atlanta,
Georgia
| – | +$218 | +3 | New |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | +$509 | +7 | New |
|
ATOS Hedge Fund Activity: Q4 2017 in Review
12 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q4 2017, worth a combined $175K — down 63% from $478K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ATOS positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $30.8K. The largest seller was Renaissance Technologies, cutting an estimated $131K.
- 12 institutional investors held Atossa Therapeutics (ATOS) as of Q4 2017, up from 11 in Q3 2017.
- Funds reported $175K of Atossa Therapeutics stock for Q4 2017, down 63% quarter-over-quarter.
- 4 funds opened new Atossa Therapeutics positions in Q4 2017 and 3 closed out, a net change of +1 holder.
- The largest Atossa Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $30.8K added.
- The largest Atossa Therapeutics seller in Q4 2017 was Renaissance Technologies, an estimated $131K sold.
Based on aggregated 13F filings for Q4 2017.